Exhibit 16.1
January 20, 2023
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Commissioners:
We have read the statements made by Peak Pharmaceuticals, Inc. under Item 4.01 of its Form 8-K dated January 20, 2023. We agree with the statements concerning our firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Peak Pharmaceuticals, Inc. contained therein.
Very truly yours,
/s/ Friedman LLP
Marlton, New Jersey